HMFR
What it found
We found no results in the registry or in papers.
What was tested
Treatment tested
- Duloxetine
What it measured
Main measures
The primary efficacy measure is the weekly mean of the 24-hour average pain severity assessed daily by each patient, via daily diary, using an 11-point Likert scale.
Pain
Who could take part
MS (type not specified)
Inclusion: [1] Present with central neuropathic pain due to MS based on the disease diagnostic criteria Exclusion: [12] Are investigator site personnel directly affiliated with this study and/or their immediate families
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
to assess the efficacy of duloxetine 60 mg once daily (QD) compared with placebo on the reduction of central neuropathic pain severity as measured by the weekly mean of the daily 24-hour average pain scores in patients with central neuropathic pain due to MS assessed using an 11-point Likert scale and collected via daily patient diary at the end of 6 weeks of treatment.
Loading reviews and guidelines…
Related trials
- QSIT
Phase 1 / Phase 2 · Enrolling by invitation
Still running
- DRI_2020/03
Phase 3 · Not yet recruiting
Still running
- Ketamine for MS Fatigue
Early phase 1 · Completed
Result in a paper, not read yet
- INKLING-MS
Phase 2 · Running, not recruiting
Still running
- Ketamine for Treatment of MS Fatigue
Phase 1 / Phase 2 · Completed
Results posted, no main test reported
- Treatment of Pendular Nystagmus in OPT
Phase 4 · Completed
Result in a paper, not read yet
History
Started
Jul 2008
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error